Antiplatelet Therapy for Secondary CVD Prevention: So Many Choices; What Should We Do?
A series of Live Grand Rounds Programs and a CME-certified Webcourse.
Antiplatelet Therapy for Secondary CVD Prevention: So Many Choices; What Should We Do?
This CME-certified initiative is intended for all health professionals who are part of the multidisciplinary care team for patients with MI, ACS, or PAD. A series of live CME-certified grand rounds will be presented at selected hospitals throughout the US during 2015, and an online CME-certified webcourse will be available in late 2015.
Antithrombotic therapy provides secondary prevention for high-risk CVD patients and it is becoming apparent that longer-term therapies can further reduce recurrences. However, questions remain regarding which antithrombotic therapy should be used to meet the needs of individual patients; how/when to switch therapies; the potential role of concomitant therapies; and prospects for secondary prevention in other high-risk populations. “Antiplatelet Therapy for Secondary CVD Prevention” will explore which patients are appropriate candidates for which therapies and which patients need longer-term antiplatelet therapies for secondary prevention. The program will also encourage all members of the heart team and their patients to work in synergy to reduce recurrent ACS events, reduce hospital readmissions, and improve overall outcomes.
This CME-certified initiative is intended for hospital staff members who specialize in cardiology, interventional cardiology, vascular surgery, and interventional radiology, as well as fellows, residents, and other healthcare professionals interested in atherosclerotic cardiovascular disease.
Appraise the clinical data supporting long-term use of antithrombotics in patients with a history of CVD
Analyze processes of switching therapies or employing concomitant therapies to achieve optimal balance of anti-ischemic protection vs bleeding risk
Customize longer-term therapies to the needs of particular patients, taking into consideration the evolving landscape of additional indications
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email firstname.lastname@example.org.
Click here for the CME-certified webcourse associated with this program.
Live Program Materials for Speakers and Administrators
Back to Top
I. Administrator Material
II. Speaker Material
Thank you for joining us as an expert speaker for the Grand Rounds Series, Antiplatelet Therapy for Secondary CVD Prevention: So Many Choices; What Should We Do?
This orientation will familiarize you with the complete slide set,provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:
- Appraise the clinical data supporting various long-term antithrombotic treatment options for patients with a history of CVD
- Ascribe to best practice approaches to consider switching therapies or employing concomitant therapies to achieve optimal balance of anti-ischemic protection vs bleeding risk
- Customize longer-term therapies to the needs of particular patients, taking into consideration the evolving landscape of additional indications
Transcript of Speaker Orientation Download (PDF)
Audio download of Speaker Orientation
CME-certified Program Slides
This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)
Steering Committee and Speaker Biographies
Deepak L. Bhatt, MD, MPH
Executive Director, Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Professor of Medicine, Harvard Medical School
Deepak L. Bhatt, MD, MPH is Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. He is also a Senior Physician at Brigham and Women’s Hospital and a Senior Investigator in the TIMI Study Group.
After graduating as valedictorian from the Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology, while also serving as a Research Associate at Harvard Medical School. He received his medical doctorate from Cornell University. He completed a Masters in Public Health with a concentration in clinical effectiveness at Harvard University. His internship and residency in internal medicine were performed at the Hospital of the University of Pennsylvania, and his cardiovascular training was at the Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention, as well as serving as Chief Interventional Fellow at Cleveland Clinic, where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship and as Associate Director of the Cardiovascular Medicine Fellowship. He also served as Associate Director of the Cleveland Clinic Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System, where he served for several years. Dr. Bhatt has been listed in
Best Doctors in America
from 2005 to 2014.
Dr. Bhatt’s research interests include acute coronary syndromes, preventive cardiology, and advanced techniques in cardiac, cerebral, and peripheral intervention. He has authored or co-authored more than 600 publications. He is the editor of
Atherothrombosis in Clinical Practice
published by Oxford University Press and of
Perpiheral and Cerebrovascular Intervention
published by Springer. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as Chair of COGENT and helped lead STAMPEDE. He serves as Co-chair of the REACH registry and chairs REDUCE-IT. He is co-PI of SAVOR-TIMI 53, SYMPLICITY HTN-3, and THEMIS. He is the current Chair of the AHA-GWTG Steering Committee. He is Associate Editor for clinical trials for the ACC’s Cardiosource. Dr. Bhatt has been a visiting lecturer at a number of prestigious institutions throughout the world, and has been interviewed extensively by news agencies on numerous topics. He is the Editor of the peer-reviewed
Journal of Invasive Cardiology,
Chief Medical Editor of
Cardiology Today’s Intervention
for healthcare professionals, and Editor-in-Chief of the
Harvard Heart Letter
Christopher P. Cannon, MD
Executive Director of Cardiometabolic Trials
Harvard Clinical Research Institute
Professor of Medicine
Harvard Medical School
Senior Physician, Cardiovascular Division
Brigham and Women’s Hospital
Christopher P. Cannon, MD is a Professor of Medicine at Harvard Medical School, and Senior Physician in the Cardiovascular Division at Brigham and Women’s Hospital. He earned his medical doctorate from Columbia University College of Physicians and Surgeons in New York, then completed his internal medicine residency at Columbia Presbyterian Medical Center and his cardiovascular fellowship at Brigham and Women’s Hospital.
Dr. Cannon has published more than 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 17 books. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association.
As a Senior Investigator of the TIMI Study Group, he has been Principal Investigator of more than 15 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, and the IMPROVE IT trial. Dr. Cannon also serves as Executive Director of Cardiometabolic Trials at the Harvard Clinical Research Institute (HCRI). He is leading the RE-DUAL PCI trial, studying novel anticoagulant strategies in patients with atrial fibrillation undergoing stenting, and collaborates on many other trials and registry projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids, and prevention.